According to Frost & Sullivan data, the global surgical robot market grew from $4.44 billion in 2017 to $10.91 billion in 2021, with a compound annual growth rate of 25.2%. The global surgical robot market is expected to reach $28.51 billion in 2025 and $61.9 billion in 2030. In 2021, the size of China's surgical robot market is about CNY 5.1 billion, and it is expected to grow at a compound annual growth rate of 42.61% in the next five years. By 2026, the market size is expected to reach CNY 30 billion, and by 2032, it is expected to reach CNY 182.9 billion.

The global surgical robot market is expected to reach $28.51 billion by 2025, with a compound annual growth rate of 27.1% from 2021 to 2025.

By 2030, the global surgical robot market will reach $61.9 billion, and the compound annual growth rate from 2025 to 2030 will be 16.8%.

Surgical robots can be divided into orthopedic surgical robots, laparoscopic surgical robots, oral surgical robots, etc.

The da Vinci Surgical System is currently the most successful surgical robot product in the world.

In December 2023, the first domestically produced da Vinci surgical robot will officially settle in Gansu Hospital of Zhongshan University Cancer Hospital, marking the formal localization of the da Vinci surgical robot.

According to Frost & Sullivan data, the global surgical robot market grew from $4.44 billion in 2017 to $10.91 billion in 2021, with a compound annual growth rate of 25.2%. The global surgical robot market is expected to reach $28.51 billion in 2025 and $61.9 billion in 2030. In 2021, the size of China's surgical robot market is about CNY 5.1 billion, and it is expected to grow at a compound annual growth rate of 42.61% in the next five years. By 2026, the market size is expected to reach CNY 30 billion, and by 2032, it is expected to reach CNY 182.9 billion.

At present, the business model of China's surgical robot industry is mainly driven by the installation of surgical robot equipment in hospitals to promote the sales of surgical consumables and services.

In the future, with the strong support of China's aging population trend, medical insurance policies and industry development, the overall industry development prospects are broad.

Sinolink Securities released a research report stating that on March 13, the State Council issued the "Action Plan for Promoting Large-scale Equipment Updating and Consumer Goods Trade-ins", and the bank believes that the release of this State Council document will be conducive to the development of the medical device industry in the future, and the innovative research and development enthusiasm of enterprises will be stimulated. The market capacity and penetration rate of medical devices may be improved, and domestic medical device industry leading companies are expected to gain more market share with lower costs and product technology advantages.

Surgical robot related companies:

Fosun Pharma (02196): Fosun Pharma has entered this field through its subsidiary Visual Fosun Medical Device Technology (Shanghai) Co., Ltd. (referred to as "Visual Fosun"). Recently, the "Visual Fosun Headquarters Industrial Base Launch Ceremony" was held in Shanghai. It is reported that the total investment of the project base is about CNY 0.7 billion, which is also the largest R&D, production, and training integrated base of Intuitive Medical Company in the Asia-Pacific region. The new headquarters base will initially focus on the production of parts for da Vinci surgical robots and Ion systems. Industry insiders said that the approval and listing of multiple domestic surgical robots in recent years shows that the innovation and R&D capabilities of the industry are constantly improving, which has a great promotion effect on related clinical expansion applications. Driven by multiple bullish factors such as market demand, policy support, and technological progress, the domestic surgical robot industry will usher in greater development space.

MicroPort Robotic (02252): It is expected that the company's revenue for the six months ending June 30, 2024 will increase by approximately 103% to 108% compared to the six months ending June 30, 2023. Tumorai was approved for listing by NMPA on January 27, 2022 (applied to urology), It is the first and only four-arm laparoscopic surgical robot independently developed by a Chinese company. In October 2023, it was granted approval for application in multiple departments such as urology, general surgery, gynecology, and thoracic surgery. In 2023, Tumorai has completed the sale of multiple products and won bids in more than 15 domestic hospitals, ranking first in domestic brands of laparoscopic surgical robots in terms of sales volume; Honghu, the company's hip-knee-integrated orthopedic surgical robot, was approved for listing for TKA surgery, and became the first domestically approved bone and joint surgical robot with independently developed mechanical arms that is compatible with TKA and THA. It obtained FDA 510(K) certification in July 2022, and CE certification in Asia, North America, South America, Europe, and Oceania in December 2022, which is a key milestone for the company's global strategy. Currently, Honghu has won/installed multiple orders domestically and abroad, and the cumulative order delivery has exceeded 20 units, and more than 800 clinical robotic assisted surgeries have been completed in departments such as orthopedics, joint surgery, and sports medicine in more than 40 hospitals in 16 provinces and cities in China.

AK Medical (01789): The joint surgical robot system was recently approved for listing.